A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France
A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France
Alprolix (rFIXFc) is a recombinant extended half-life coagulation factor product. The purpose
 of this non-interventional study is to describe the real-world usage and effectiveness of
 Alprolix in the on-demand and prophylactic treatment of haemophilia B.
Inclusion Criteria:

 -  Have a diagnosis of haemophilia B and been treated previously with factor IX Product

 -  Have started Alprolix treatment prior to enrolment visit, or at enrolment prescribed
 treatment with Alprolix, regardless of participation in the study

 -  Signed and dated informed consent provided by the patient, or the patient's legally
 acceptable representative for patients under the legal age, before any study-related
 activities are undertaken. Assent should be obtained from paediatric patients
 according to local regulations

 Exclusion Criteria:

 -  Participation in an investigational medicinal product trial at enrolment visit